SKF-82,958: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
No edit summary
Line 25: Line 25:
}}
}}


'''SKF 82958''' ('''C-APB''') is a synthetic compound that acts as a [[dopamine receptor]] [[D1_receptor|D<sub>1</sub>]] [[agonist]].<ref>{{cite journal | author = Pfeiffer, Francis R.; Wilson, James W.; Weinstock, Joseph; Kuo, George Y.; Chambers, Pamela A.; Holden, Kenneth G.; Hahn, Richard A.; Wardell, Joseph R., Jr.; Alfonso, J. Tobia; et al. | title = Dopaminergic activity of substituted 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines | journal = [[Journal of Medicinal Chemistry]] | year=1982 | volume=25 | issue=4 | pages =352-358}}</ref> The abbreviation SKF stands for [[Smith, Kline & French]], a pharmaceutical company which later became [[GlaxoSmithKline]]. SKF 82958 and similar D<sub>1</sub>-selective full agonists produce characteristic anorectic effects, hyperactivity and self-administration in animals, with a similar but not identical profile to that of dopaminergic stimulants such as amphetamine.<ref name="pmid1365854">{{cite journal |author=Terry P, Katz JL |title=Differential antagonism of the effects of dopamine D1-receptor agonists on feeding behavior in the rat |journal=Psychopharmacology |volume=109 |issue=4 |pages=403–9 |year=1992 |pmid=1365854 |doi= |url=}}</ref><ref name="pmid1356585">{{cite journal |author=Self DW, Stein L |title=The D1 agonists SKF 82958 and SKF 77434 are self-administered by rats |journal=Brain Research |volume=582 |issue=2 |pages=349–52 |year=1992 |month=June |pmid=1356585 |doi= |url=}}</ref><ref name="pmid7862937">{{cite journal |author=Rosenzweig-Lipson S, Hesterberg P, Bergman J |title=Observational studies of dopamine D1 and D2 agonists in squirrel monkeys |journal=Psychopharmacology |volume=116 |issue=1 |pages=9–18 |year=1994 |month=September |pmid=7862937 |doi= |url=}}</ref><ref name="pmid7623160">{{cite journal |author=Kalivas PW, Duffy P |title=D1 receptors modulate glutamate transmission in the ventral tegmental area |journal=The Journal of Neuroscience : the Official Journal of the Society for Neuroscience |volume=15 |issue=7 Pt 2 |pages=5379–88 |year=1995 |month=July |pmid=7623160 |doi= |url=}}</ref><ref name="pmid8531104">{{cite journal |author=Weed MR, Woolverton WL |title=The reinforcing effects of dopamine D1 receptor agonists in rhesus monkeys |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=275 |issue=3 |pages=1367–74 |year=1995 |month=December |pmid=8531104 |doi= |url=}}</ref><ref name="pmid9336305">{{cite journal |author=Weed MR, Paul IA, Dwoskin LP, Moore SE, Woolverton WL |title=The relationship between reinforcing effects and in vitro effects of D1 agonists in monkeys |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=283 |issue=1 |pages=29–38 |year=1997 |month=October |pmid=9336305 |doi= |url=}}</ref><ref name="pmid9570457">{{cite journal |author=Abrahams BS, Rutherford JD, Mallet PE, Beninger RJ |title=Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434 |journal=European Journal of Pharmacology |volume=343 |issue=2-3 |pages=111–8 |year=1998 |month=February |pmid=9570457 |doi= |url=}}</ref><ref name="pmid9618419">{{cite journal |author=Tidey JW, Bergman J |title=Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=285 |issue=3 |pages=1163–74 |year=1998 |month=June |pmid=9618419 |doi= |url=}}</ref><ref name="pmid10881041">{{cite journal |author=Berridge KC, Aldridge JW |title=Super-stereotypy I: enhancement of a complex movement sequence by systemic dopamine D1 agonists |journal=Synapse (New York, N.Y.) |volume=37 |issue=3 |pages=194–204 |year=2000 |month=September |pmid=10881041 |doi=10.1002/1098-2396(20000901)37:3<194::AID-SYN3>3.0.CO;2-A |url=}}</ref>
'''SKF 82958''' is a synthetic compound that acts as a [[D1_receptor|D<sub>1</sub>]] and [[D2_receptor|D<sub>2</sub> receptor]] [[agonist]].<ref>{{cite journal | author = Pfeiffer, Francis R.; Wilson, James W.; Weinstock, Joseph; Kuo, George Y.; Chambers, Pamela A.; Holden, Kenneth G.; Hahn, Richard A.; Wardell, Joseph R., Jr.; Alfonso, J. Tobia; et al. | title = Dopaminergic activity of substituted 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines | journal = [[Journal of Medicinal Chemistry]] | year=1982 | volume=25 | issue=4 | pages =352-358}}</ref> The abbreviation SKF stands for [[Smith, Kline & French]], a pharmaceutical company which later became [[GlaxoSmithKline]].


{{pharm-stub}}
{{pharm-stub}}

Revision as of 07:01, 20 July 2009

SKF-82,958
Names
IUPAC name
3-Allyl-6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
Identifiers
3D model (JSmol)
  • C=CCN1CCC2=C(C(=C(C=C2C(C1)C3=CC=CC=C3)O)O)Cl
Properties
C19H20ClNO2
Molar mass 329.82 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

SKF 82958 (C-APB) is a synthetic compound that acts as a dopamine receptor D1 agonist.[1] The abbreviation SKF stands for Smith, Kline & French, a pharmaceutical company which later became GlaxoSmithKline. SKF 82958 and similar D1-selective full agonists produce characteristic anorectic effects, hyperactivity and self-administration in animals, with a similar but not identical profile to that of dopaminergic stimulants such as amphetamine.[2][3][4][5][6][7][8][9][10]

Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

References

  1. ^ Pfeiffer, Francis R.; Wilson, James W.; Weinstock, Joseph; Kuo, George Y.; Chambers, Pamela A.; Holden, Kenneth G.; Hahn, Richard A.; Wardell, Joseph R., Jr.; Alfonso, J. Tobia; et al. (1982). "Dopaminergic activity of substituted 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines". Journal of Medicinal Chemistry. 25 (4): 352–358. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  2. ^ Terry P, Katz JL (1992). "Differential antagonism of the effects of dopamine D1-receptor agonists on feeding behavior in the rat". Psychopharmacology. 109 (4): 403–9. PMID 1365854.
  3. ^ Self DW, Stein L (1992). "The D1 agonists SKF 82958 and SKF 77434 are self-administered by rats". Brain Research. 582 (2): 349–52. PMID 1356585. {{cite journal}}: Unknown parameter |month= ignored (help)
  4. ^ Rosenzweig-Lipson S, Hesterberg P, Bergman J (1994). "Observational studies of dopamine D1 and D2 agonists in squirrel monkeys". Psychopharmacology. 116 (1): 9–18. PMID 7862937. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  5. ^ Kalivas PW, Duffy P (1995). "D1 receptors modulate glutamate transmission in the ventral tegmental area". The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. 15 (7 Pt 2): 5379–88. PMID 7623160. {{cite journal}}: Unknown parameter |month= ignored (help)
  6. ^ Weed MR, Woolverton WL (1995). "The reinforcing effects of dopamine D1 receptor agonists in rhesus monkeys". The Journal of Pharmacology and Experimental Therapeutics. 275 (3): 1367–74. PMID 8531104. {{cite journal}}: Unknown parameter |month= ignored (help)
  7. ^ Weed MR, Paul IA, Dwoskin LP, Moore SE, Woolverton WL (1997). "The relationship between reinforcing effects and in vitro effects of D1 agonists in monkeys". The Journal of Pharmacology and Experimental Therapeutics. 283 (1): 29–38. PMID 9336305. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  8. ^ Abrahams BS, Rutherford JD, Mallet PE, Beninger RJ (1998). "Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434". European Journal of Pharmacology. 343 (2–3): 111–8. PMID 9570457. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  9. ^ Tidey JW, Bergman J (1998). "Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs". The Journal of Pharmacology and Experimental Therapeutics. 285 (3): 1163–74. PMID 9618419. {{cite journal}}: Unknown parameter |month= ignored (help)
  10. ^ Berridge KC, Aldridge JW (2000). "Super-stereotypy I: enhancement of a complex movement sequence by systemic dopamine D1 agonists". Synapse (New York, N.Y.). 37 (3): 194–204. doi:10.1002/1098-2396(20000901)37:3<194::AID-SYN3>3.0.CO;2-A. PMID 10881041. {{cite journal}}: Unknown parameter |month= ignored (help)
Retrieved from "https://en.wikipedia.org/w/index.php?title=SKF-82,958&oldid=303088304"